| Nov 16 |
BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)
|
| Nov 14 |
BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ...
|
| Nov 14 |
BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript
|
| Nov 13 |
BioCardia GAAP EPS of -$0.61 beats by $0.58
|
| Nov 13 |
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
|
| Nov 13 |
Earnings Scheduled For November 13, 2024
|
| Nov 6 |
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
|
| Oct 28 |
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
|
| Oct 9 |
BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
|
| Sep 18 |
BioCardia regains compliance with Nasdaq Capital Market
|
